Best to email managment to explain this but my understanding is that the US market is set up to ‘reimburse’ the ongoing service element by nurses etc for this device DYOR
This is clearly an inflection point. The patient investors (who have been very very patient) I believe will be vindicated. This should become evident from now on as the hard work selling this to potential parties starts to become real as people get approvals and sign up and get started with using it as a part of their standard of care.
